Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of Atroshi-Lyrén 6-item Symptoms Scale
Launched by ILKE KARA · Jul 24, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating a Turkish version of a questionnaire called the Atroshi-Lyrén 6-item Symptoms Scale (A-L scale) to help understand the symptoms of Carpal Tunnel Syndrome (CTS). The goal is to make sure this new version is accurate and reliable for Turkish-speaking patients. Carpal Tunnel Syndrome is a condition that can cause numbness, tingling, weakness, and pain in the hands, often due to pressure on a nerve in the wrist.
To take part in the study, participants need to be between 18 and 65 years old and have been experiencing symptoms like those mentioned for at least a month. They should not have conditions like diabetes or rheumatoid arthritis, as these could affect the results. If eligible, participants will help researchers test this new scale, which may improve how doctors understand and treat carpal tunnel syndrome in Turkish-speaking patients. The study is currently looking for volunteers to join, so anyone interested can reach out for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged between 18-65 years old,
- • Had symptoms of numbness, tingling, weakness and pain in the hands for at least 1 month,
- • Assessed through provocation tests and physical examination to match the median nerve distribution.
- Exclusion Criteria:
- • Not willing to participate in the study,
- • Clinical or electrophysiological signs of proximal nerve compression,
- • Diabetes or other metabolic disease,
- • Rheumatoid arthritis or other general inflammatory diseases.
About Ilke Kara
Ilke Kara is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial designs and robust methodologies. With a focus on collaboration and transparency, Ilke Kara partners with healthcare professionals, academic institutions, and biopharmaceutical companies to facilitate the development of new therapies across various therapeutic areas. Their expertise in regulatory compliance and patient-centric approaches ensures the integrity of clinical data and enhances participant engagement, ultimately contributing to the acceleration of drug development and the delivery of safe and effective treatments to the market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bitlis, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported